Patent intelligence · EP
EP 3576795
ORALES SCHILDDRÜSENTHERAPEUTIKUM
ORALES SCHILDDRÜSENTHERAPEUTIKUM
Patent details — EP 3576795
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Dec 11, 2019
- Expiration
- Dec 6, 2039
- Applicant
- BERLIN CHEMIE AG [DE]
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 198 A I, A61K 47/ 18 A I, A61K 47/ 20 A I
Quick answer
EP 3576795 (ORALES SCHILDDRÜSENTHERAPEUTIKUM) is held by BERLIN CHEMIE AG [DE]. Status: granted. Granted Dec 11, 2019. Expires Dec 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BERLIN CHEMIE AG [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 198 A I, A61K 47/ 18 A I, A61K 47/ 20 A I, A61K/31198, A61K/4720
More from BERLIN CHEMIE AG [DE]
Related pharmaceutical patents in our USPTO index.
-
WO 2024252263
COMPOSITIONS SOLIDES DE DICHLORHYDRATE D'ÉLACESTRANT, LEURS PROCÉDÉS DE FABRICATION ET MÉTHODES DE TRAITEMENT LES UTILISANT
granted -
WO 2024023766
POLYTHÉRAPIE À BASE D'INHIBITEUR DE P13K
granted -
CA 3259243
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE BCL-2
granted -
CA 3259252
POLYTHÉRAPIE ANTICANCÉREUSE COMPRENANT UN INHIBITEUR DE FLT3
granted -
WO 2022029639
FORMULATIONS PHARMACEUTIQUES AMÉLIORÉES COMPRENANT DES INHIBITEURS DE PI3K
granted -
US 2021015826
ANTICANCER PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY
granted -
US 2020040086
PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted
Frequently asked questions
What is US patent 3576795?
EP 3576795 (ORALES SCHILDDRÜSENTHERAPEUTIKUM) is held by BERLIN CHEMIE AG [DE]. Status: granted. Granted Dec 11, 2019. Expires Dec 6, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 3576795?
BERLIN CHEMIE AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 3576795 expire?
Our index shows an expiration date of Dec 6, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.